Abstract
Clinical studies suggest that treatment with vaccines comprised of idiotype protein may be associated with improved clinical outcome in follicular lymphoma patients. The time-consuming process required to generate patient-specific vaccines is a major limitation, however. Here we report results of a pilot clinical trial with a novel autologous, tumor-derived proteoliposome vaccine formulation that could be rapidly produced within a single day. Vaccination was safe, induced autologous tumor-specific type 1 cytokine responses in 5 out of 10 follicular lymphoma patients, and was associated with induction of a sustained complete response in one patient. Other patients had large tumor burdens and progressed after a median duration of 8 months. These results suggest that further testing of this vaccine formulation, particularly in the setting of minimal disease, is warranted. Furthermore, the proteoliposome formulation may provide a model for vaccine development for other human cancers, for which tumor-associated antigens need not be defined.
Original language | English (US) |
---|---|
Pages (from-to) | 5160-5163 |
Number of pages | 4 |
Journal | Blood |
Volume | 109 |
Issue number | 12 |
DOIs | |
State | Published - Jun 15 2007 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
MD Anderson CCSG core facilities
- Flow Cytometry and Cellular Imaging Facility